Colorectal Cancer: Catching It Early

January 8, 2018

Colorectal cancer is one of the most common types of cancer and is a leading cause of cancer-related deaths in the United States. If all adults 45 and older were screened for colorectal cancer we could avoid thousands of deaths each year and prevent many people from ever getting the disease.

Spotlight

Pierre Fabre Group

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2017, it generated 2,318 million euros in net sales, of which 62% came from its international business and 62% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,500 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2017, Pierre Fabre dedicated almost 143 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.

Other Infographics
news image

COVID-19 Summary as of March 13, 2020

Infographic | April 6, 2020

Biomedtracker and Trialtrove have a total of 307 clinical trials for the treatment of COVID-19. 152 initiated trials for the treatment of COVID-19. 155 Trials have been announced but have not yet begun recruitment.

Read More
news image

2021 global life sciences outlook

Infographic | August 24, 2021

The life sciences sector has played a pivotal role amid the COVID-19 pandemic. To cope with the global crisis, traditional competitors partnered to accelerate research and develop the fastest novel vaccine in the history. Governments, health systems, payers, retail pharmacies, and nonprofits are now working collaboratively with the sector to provide widespread distribution and administration.

Read More
news image

Pharmaceutical industry and medicine

Infographic | March 12, 2022

Pharmaceutical industry and medicine vector infographics with drugs, pills, bottles and packages, text blocks and charts all around

Read More
news image

What is Adoptive Cell Therapy?

Infographic | February 5, 2020

A type of immunotherapy in which T cells are given to a patient to help the body fight diseases. In cancer therapy, T cells are usually taken from the patient’s own blood or tumor tissue, grown in large numbers in the laboratory, and then given back to the patient to help the immune system fight the cancer.

Read More
news image

Pharma Technology Focus

Infographic | June 3, 2022

Pharma Technology Focus is free to read on all devices.

Read More
news image

Cancer Drugs Bring in Most Pharma Revenue

Infographic | February 25, 2020

Worldwide cancer drug sales are already way ahead of those of other drugs and the revenue generated by them is expected to grow even larger by 2024. This is according to a report recently released by consultancy Evaluate, which analyses trends in the pharmaceutical sector. According to Evaluate's calculations, oncology drugs reached US$123.8 billion in sales in 2018, more than double that of the next item on the list, drugs treating diabetes with US$48.5 billion dollars in sales. By 2024, cancer drug sales are expected to almost double to US$236.6 billion dollars.

Read More

Spotlight

Pierre Fabre Group

Pierre Fabre is the 2nd largest dermo-cosmetics laboratory in the world and the 2nd largest private French pharmaceutical group. In 2017, it generated 2,318 million euros in net sales, of which 62% came from its international business and 62% from its dermo-cosmetics division. Pierre Fabre, which has always been headquartered in the South-West of France, owns subsidiaries in 43 countries, enjoys distribution agreements in over 130 countries and counts around 13,500 employees worldwide. Pierre Fabre’s portfolio represents a continuum of activities spanning from prescription drugs and consumer health care products to dermo-cosmetics. In 2017, Pierre Fabre dedicated almost 143 million euros to R&D, shared between oncology, dermatology, the central nervous system, consumer health care and dermo-cosmetics.

Events